Skip to main content
Mauna Kea Technologies logo

Mauna Kea Technologies — Investor Relations & Filings

Ticker · MKEA ISIN · FR0010609263 LEI · 5493007KMDG4MFIGJJ63 PA Manufacturing
Open in API
Filings indexed 774 across all filing types
Latest filing 2025-03-03 Regulatory Filings
Country FR France
Listing PA MKEA

About Mauna Kea Technologies

https://www.maunakeatech.com/en/

Mauna Kea Technologies is a medical device company that develops and markets the Cellvizio® platform, a real-time in vivo cellular imaging system. The platform utilizes Confocal Laser Endomicroscopy (CLE) technology, enabling physicians to visualize tissue at the cellular level during medical procedures. This "optical biopsy" is performed using flexible, miniature fiber-optic probes (Confocal Miniprobes™) that are compatible with standard endoscopes. The core function of Cellvizio® is to provide immediate microscopic visualization, which aids in accelerating diagnosis, informing treatment strategies, and improving the precision of therapeutic interventions. Key applications include gastroenterology (for conditions such as Barrett's esophagus and pancreatic cysts), interventional pulmonology (lung cancer diagnostics), urologic oncology, and neurosurgery. The technology supports enhanced surgical procedures, including real-time margin assessment, and is being integrated with robotic surgery and AI-assisted imaging systems.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Regulatory Filings Classification · 100% confidence The document is a press release dated March 3, 2025, announcing that the European Society of Gastrointestinal Endoscopy (ESGE) has issued a recommendation for the use of nCLE with Cellvizio® for pancreatic cyst diagnosis. It contains quotes from management and medical professionals, discusses clinical studies, and concludes with boilerplate information about the company and a disclaimer referencing the 2023 Annual Report. This format—a formal announcement of a significant business/clinical development, often released outside of standard SEC filing cycles—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is not a full financial report (like 10-K or IR), nor a transcript (CT), nor a specific voting/insider/dividend notice, it fits best as an Earnings Release (ER) if it were tied to a reporting period, or a general Regulatory Filing (RNS). Given the content is a major positive clinical/commercial update rather than a summary of financial results, RNS is a strong candidate, but ERs often include significant operational news alongside financial highlights. However, the structure strongly resembles a standard press release announcing a major event/endorsement, which often falls under the general 'Regulatory Filings' (RNS) category if no other specific code applies, or sometimes an Earnings Release (ER) if it's the primary communication vehicle for the period's news. Since it is not explicitly an earnings summary but a major operational/clinical announcement, RNS is the most appropriate general regulatory category for non-standard announcements.
2025-03-03 English
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Regulatory Filings Classification · 95% confidence The document is a standard regulatory disclosure required by French law (Article L233-8-II of the Commercial Code and Article 223-16 of the AMF General Regulation) regarding the total number of voting rights and shares composing the share capital. This type of filing is a routine regulatory update on capital structure and does not fit into specific categories like 'Share Issue' (which would be a specific transaction announcement) or 'Major Shareholding' (which would be a notification of a threshold crossing). Therefore, it falls under the 'Regulatory Filings' (RNS) category as a general regulatory announcement.
2025-02-06 French
Total number of voting rights and capital / Information on the total number of voting rights and the number of shares making up the capital
Regulatory Filings Classification · 95% confidence The document is a monthly disclosure of the total number of voting rights and shares comprising the share capital, as required by Article L233-8-II of the French Commercial Code and Article 223-16 of the AMF General Regulations. This type of regulatory disclosure regarding share capital and voting rights, which does not involve a specific transaction in own shares or a major shareholding notification, is best classified as a general regulatory filing.
2025-02-06 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release from Mauna Kea Technologies announcing clinical results for a new surgical application of their Cellvizio technology. It does not report financial results, board changes, or regulatory filings, but rather provides a corporate update on product utility and clinical research. As it is a general corporate announcement that does not fit into specific financial reporting categories, it is classified as a Regulatory Filing (RNS).
2025-01-27 French
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is a press release issued by Mauna Kea Technologies announcing clinical results for their Cellvizio platform in a new surgical application. It does not contain financial statements, audit reports, or regulatory filings, but rather serves as a general corporate announcement regarding product utility and research findings. As it does not fit into specific categories like earnings releases or governance reports, it falls under the general regulatory/corporate announcement category.
2025-01-27 English
Acquisition or disposal of the issuer's own shares / Information relating to the liquidity contract
Transaction in Own Shares Classification · 100% confidence The document is a 'Half-Year Liquidity Contract Statement' detailing the share buyback and sell-side activity conducted by a brokerage firm on behalf of Mauna Kea Technologies. This type of disclosure is a standard regulatory requirement for companies to report on their share repurchase programs and liquidity contracts. Since it specifically details the transactions of the company's own shares, it falls under the 'Transaction in Own Shares' category. H2 2024
2025-01-21 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.